What is Zacks Research’s Estimate for RVPH FY2026 Earnings?

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Research analysts at Zacks Research lowered their FY2026 earnings estimates for Reviva Pharmaceuticals in a report released on Wednesday, April 1st. Zacks Research analyst J. Vandermosten now anticipates that the company will post earnings of ($2.21) per share for the year, down from their previous forecast of ($2.20). The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.97) per share. Zacks Research also issued estimates for Reviva Pharmaceuticals’ FY2027 earnings at ($1.74) EPS.

A number of other research analysts have also weighed in on RVPH. D. Boral Capital lowered Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 5th. Wall Street Zen raised Reviva Pharmaceuticals to a “sell” rating in a report on Saturday, March 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research note on Thursday, January 22nd. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Reviva Pharmaceuticals in a report on Tuesday, December 23rd. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $40.00 price target on shares of Reviva Pharmaceuticals in a research report on Monday, January 5th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Reviva Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $66.67.

Reviva Pharmaceuticals Stock Performance

RVPH stock opened at $0.72 on Friday. The firm has a 50 day moving average price of $3.67 and a 200-day moving average price of $7.64. Reviva Pharmaceuticals has a 52-week low of $0.59 and a 52-week high of $23.20. The firm has a market capitalization of $9.22 million, a price-to-earnings ratio of -0.08 and a beta of 0.64.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in RVPH. XTX Topco Ltd bought a new position in Reviva Pharmaceuticals in the 2nd quarter valued at approximately $31,000. Lido Advisors LLC bought a new stake in shares of Reviva Pharmaceuticals in the 3rd quarter worth $37,000. NewEdge Advisors LLC purchased a new position in shares of Reviva Pharmaceuticals in the first quarter worth $58,000. State Street Corp lifted its holdings in shares of Reviva Pharmaceuticals by 202.4% during the fourth quarter. State Street Corp now owns 383,200 shares of the company’s stock valued at $107,000 after purchasing an additional 256,500 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Reviva Pharmaceuticals by 6.9% during the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after purchasing an additional 29,063 shares in the last quarter. 63.18% of the stock is currently owned by hedge funds and other institutional investors.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.